drugset
Drugs / GSK598809
last change May 2013 re-read 2 minutes ago

GSK598809

targets DRD3 via inhibition

Developed for
substance dependence · nicotine dependence · alcohol dependence
Investigated by
GlaxoSmithKline · Massachusetts General Hospital · Mclean Hospital · National Institute on Drug Abuse (NIDA)

Trials 8 · a red edge is where a trial was stopped

today NCT01188967 · Ph 2 NCT00793468 · Ph 2 NCT00728897 · Ph 1 NCT00728052 · Ph 1 NCT00605241 · Ph 1 NCT00468806 · Ph 1 NCT00437840 · Ph 1 NCT00437632 · Ph 1
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 16 trials
Phase 1 NCT00728897 Jul 2008 substance dependence GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT00728052 Jun → Aug 2008 substance dependence GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT00605241 Feb 2008 → Mar 2009 substance dependence GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT00468806 Apr 2007 → May 2008 — GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT00437840 Mar → Jun 2007 substance dependence GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT00437632 Mar 2007 → Aug 2008 substance dependence GlaxoSmithKline Completed No outcome recorded
Phase 22 trials
Phase 2 NCT01188967 Aug 2010 → May 2013 nicotine dependence Massachusetts General Hospital Completed No outcome recorded
Phase 2 NCT00793468 Dec 2008 nicotine dependence GlaxoSmithKline Withdrawn No outcome recorded
Also used as a comparator or background therapy in 3 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00908206 Comparator May → Jul 2009 alcohol dependence GlaxoSmithKline Withdrawn No outcome recorded
Phase 1 NCT01039454 Comparator Dec 2008 → Apr 2010 substance dependence GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT00887367 Comparator Sep → Dec 2008 substance dependence GlaxoSmithKline Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 12 sources stand behind the page.

FieldValueCited text
Known as GSK598809 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00887367 ↗
10

NCT00605241 ↗

NCT00728052 ↗

NCT00908206 ↗

NCT00468806 ↗

NCT00793468 ↗

NCT01039454 ↗

NCT00728897 ↗

NCT00437840 ↗

NCT00437632 ↗

NCT01188967 ↗
Action Inhibit “oral administration of various doses of the selective D(3) receptor antagonist, GSK598809” PMID 20599188 ↗ Aug 2010
Route Oral “Subjects will receive GSK598809 capsules orally with water.” NCT00437632 ↗
Target DRD3 “a selective DRD3 Antagonist” NCT00605241 ↗